Dr. Berne’s MSM eye drops and mist are unapproved new drugs; a tested lot had microbial contamination.
What happened
FDA reviewed the company’s website in August 2023 and found MSM eye drops and eye mist offered with claims that made them drugs, without an approved application. FDA laboratory testing of lot 6786 of Dr. Berne's MSM DROPS 5% Solution found microbial contamination and the sample failed USP <71> sterility tests, with Exophiala sp. and Bacillus spp. identified. During an August 21, 2023 teleconference, the company said the products are made by a contract manufacturer and agreed to a voluntary recall; it recalled lot 6786 on August 26, 2023 and all lots of several products.
What FDA found
The eye drops and eye mist are unapproved new drugs because no FDA-approved application is in effect for their uses.
FD&C Act section 505(a), 21 U.S.C. 355(a); section 301(d), 21 U.S.C. 331(d)The website and videos included claims that the products treat allergies, asthma, blepharitis, dry eye, macular degeneration, and corneal dystrophies, showing they are intended as drugs.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)Laboratory testing of lot 6786 of Dr. Berne's MSM DROPS 5% Solution found Exophiala sp. and Bacillus spp. and failed USP <71> sterility tests, making the product adulterated.
FD&C Act section 501(a)(1), 21 U.S.C. 351(a)(1)The company is responsible for the quality of its drugs even though a contract manufacturer makes them and must ensure CGMP compliance.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
What FDA wants
FDA asks the company to respond in writing within 15 working days with specific corrective steps, related documentation, and measures to prevent recurrence; if corrective action cannot be completed, the company must state why and when it will be done.
Who should pay attention
- brands that buy finished drug products from contract manufacturers
- companies selling eye drops or ophthalmic products
- quality teams managing contract manufacturer oversight and recalls
This is a summary. Read the original letter on fda.gov.